CEP
BMY.RT

Chicago Equity Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Chicago Equity Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$57K Buy
+15,015
New +$49.5K 0.01% 636

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Chicago Equity Partners's BMY.RT Position: Q1 2020 in Review

Chicago Equity Partners opened a new position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2020: 15,015 shares worth $57K. The stake represents 0.01% of the portfolio and ranks #636 among its holdings.

581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

  • Chicago Equity Partners held 15,015 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $57K as of Q1 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights was a new Chicago Equity Partners position in Q1 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up 0.01% of Chicago Equity Partners's portfolio in Q1 2020, its #636 holding.
  • 581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.